Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosimab-based treatment for unresectable stage II-III NSCLC
ChiCTR2500104164Phase 3Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jun 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Shandong Cancer Hospital. Primary endpoints: 1-year progression-free survival rate and Safety. Started Jun 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500104164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104164.